The gut microbiome and response to immune checkpoint inhibitors: preclinical and clinical strategies

Chowdhury PS, Chamoto K, Honjo T (2017) Combination therapy strategies for improving PD-1 blockade efficacy: A new era in cancer immunotherapy. J Intern Med. https://doi.org/10.1111/joim.12708 Khunger M, Hernandez AV, Pasupuleti V et al (2017) Programmed cell death 1 (PD-1) ligand (PD-L1) expression in solid tumors as a predictive biomarker of benefit from PD-1/PD-L1 axis inhibitors: a systematic review and meta-analysis. JCO Precis Oncol. https://doi.org/10.1200/po.16.00030 Dijkstra KK, Voabil P, Schumacher TN et al (2016) Genomics- and transcriptomics-based patient selection for cancer treatment with immune checkpoint inhibitors: a review. JAMA Oncol 2:1490–1495 Chalmers ZR, Connelly CF, Fabrizio D et al (2017) Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden. Genome Med 9:34 Balar AV, Weber JS (2017) PD-1 and PD-L1 antibodies in cancer: current status and future directions. Cancer Immunol Immunother 66:551–564 Zou W, Wolchok JD, Chen L (2016) PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: mechanisms, response biomarkers, and combinations. Sci Transl Med 8:328rv4 Cesano A, Warren S (2018) Bringing the next generation of immuno-oncology biomarkers to the clinic. Biomedicines. https://doi.org/10.3390/biomedicines6010014 Pagès F, Mlecnik B, Marliot F et al (2018) International validation of the consensus Immunoscore for the classification of colon cancer: a prognostic and accuracy study. Lancet 391:2128–2139 Markowiak P, Śliżewska K (2018) The role of probiotics, prebiotics and synbiotics in animal nutrition. Gut Pathog 10:21 Bin L, Yang F, Lu D et al (2016) Specific immunotherapy plus Clostridium butyricum alleviates ulcerative colitis in patients with food allergy. Sci Rep 6:25587 Shinnoh M, Horinaka M, Yasuda T et al (2013) Clostridium butyricum MIYAIRI 588 shows antitumor effects by enhancing the release of TRAIL from neutrophils through MMP-8. Int J Oncol 42:903–911 Ford AC, Quigley EM, Lacy BE et al (2014) Efficacy of prebiotics, probiotics, and synbiotics in irritable bowel syndrome and chronic idiopathic constipation: systematic review and meta-analysis. Am J Gastroenterol 109:1547–1561 Gui QF, Lu HF, Zhang CX et al (2015) Well-balanced commensal microbiota contributes to anti-cancer response in a lung cancer mouse model. Genet Mol Res 14:5642–5651 Panebianco C, Andriulli A, Pazienza V (2018) Pharmacomicrobiomics: exploiting the drug-microbiota interactions in anticancer therapies. Microbiome 6:92 Goubet AG, Daillère R, Routy B et al (2018) The impact of the intestinal microbiota in therapeutic responses against cancer. C R Biol 341:284–289 Iida N, Dzutsev A, Stewart CA et al (2013) Commensal bacteria control cancer response to therapy by modulating the tumor microenvironment. Science 342:967–970 Vétizou M, Pitt JM, Daillère R et al (2015) Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota. Science 350:1079–1084 Sivan A, Corrales L, Hubert N et al (2015) Commensal Bifidobacterium promotes antitumor immunity and facilitates anti-PD-L1 efficacy. Science 350:1084–1089 Gopalakrishnan V, Spencer CN, Nezi L et al (2017) Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients. Science. https://doi.org/10.1126/science.aan4236 Routy B, Le Chatelier E, Derosa L et al (2017) Gut microbiome influences efficacy of PD-1–based immunotherapy against epithelial tumors. Science. https://doi.org/10.1126/science.aan3706 Matson V, Fessler J, Bao R et al (2018) The commensal microbiome is associated with anti-PD-1 efficacy in metastatic melanoma patients. Science 359:104–108 Kaderbhai C, Richard C, Fumet JD et al (2017) Antibiotic use does not appear to influence response to nivolumab. Anticancer Res 37:3195–3200 Derosa L, Hellmann MD, Spaziano M et al (2018) Negative association of antibiotics on clinical activity of immune checkpoint inhibitors in patients with advanced renal cell and non-small-cell lung cancer. Ann Oncol 29:1437–1444 Chaput N, Lepage P, Coutzac C et al (2017) Baseline gut microbiota predicts clinical response and colitis in metastatic melanoma patients treated with ipilimumab. Ann Oncol 28:1368–1379 Frankel AE, Coughlin LA, Kim J et al (2017) Metagenomic shotgun sequencing and unbiased metabolomic profiling identify specific human gut microbiota and metabolites associated with immune checkpoint therapy efficacy in melanoma patients. Neoplasia 19:848–855 Sharma P, Hu-Lieskovan S, Wargo JA et al (2017) Primary, adaptive, and acquired resistance to cancer immunotherapy. Cell 168:707–723 Botticelli A, Zizzari I, Mazzuca F et al (2017) Cross-talk between microbiota and immune fitness to steer and control response to anti PD-1/PDL-1 treatment. Oncotarget 8:8890–8899 Zitvogel L, Ayyoub M, Routy B et al (2016) Microbiome and anticancer immunosurveillance. Cell 165:276–287 Yi M, Yu S, Qin S et al (2018) Gut microbiome modulates efficacy of immune checkpoint inhibitors. J Hematol Oncol 11:47 Routy B, Gopalakrishnan V, Daillère R et al (2018) The gut microbiota influences anticancer immunosurveillance and general health. Nat Rev Clin Oncol 15:382–396 Humphries A, Daud A (2018) The gut microbiota and immune checkpoint inhibitors. Hum Vaccines Immunother. https://doi.org/10.1080/21645515.2018.1442970 Gopalakrishnan V, Helmink BA, Spencer CN et al (2018) The influence of the gut microbiome on cancer, immunity, and cancer immunotherapy. Cancer Cell 33(4):570–580 Zitvogel L, Ma Y, Raoult D et al (2018) The microbiome in cancer immunotherapy: diagnostic tools and therapeutic strategies. Science 359(6382):1366–1370 Dubin K, Callahan MK, Ren B et al (2016) Intestinal microbiome analyses identify melanoma patients at risk for checkpoint-blockade-induced colitis. Nat Commun 7:10391 Dziarski R, Park SY, Kashyap DR et al (2016) Pglyrp-regulated gut microflora Prevotella falsenii, Parabacteroides distasonis and Bacteroides eggerthii enhance and Alistipes finegoldii attenuates colitis in mice. PLoS ONE 11:e0146162 Lucke K, Miehlke S, Jacobs E et al (2006) Prevalence of Bacteroides and Prevotella spp. in ulcerative colitis. J Med Microbiol 55:617–624 Andoh A, Kuzuoka H, Tsujikawa T et al (2012) Multicenter analysis of fecal microbiota profiles in Japanese patients with Crohn’s disease. J Gastroenterol 47:1298–1307 Neut C, Bulois P, Desreumaux P et al (2002) Changes in the bacterial flora of the neoterminal ileum after ileocolonic resection for Crohn’s disease. Am J Gastroenterol 97:939–946 Nguyen TL, Vieira-Silva S, Liston A et al (2015) How informative is the mouse for human gut microbiota research? Dis Model Mech 8:1–16 Ley RE, Bäckhed F, Turnbaugh P et al (2005) Obesity alters gut microbial ecology. Proc Natl Acad Sci USA 102:11070–11075 Wiles TJ, Jemielita M, Baker RP et al (2016) Host gut motility promotes competitive exclusion within a model intestinal microbiota. PLoS Biol 14:e1002517 Fessler JL, Gajewski TF (2017) The microbiota: a new variable impacting cancer treatment outcomes. Clin Cancer Res 23:3229–3231 Rolig AS, Parthasarathy R, Burns AR et al (2015) Individual members of the microbiota disproportionately modulate host innate immune responses. Cell Host Microbe 18:613–620 Letunic I, Bork P (2016) Interactive tree of life (iTOL) v3: an online tool for the display and annotation of phylogenetic and other trees. Nucleic Acids Res 44(Web Server issue):W242–W245. https://doi.org/10.1093/nar/gkw290